OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2019.9931 OL-0-0-9931 Articles Metachronous bilateral triple-negative breast cancer associated with neurofibromatosis type 1: A case report YamagishiYoji 1 2 EinamaTakahiro 2 YamasakiTamio 2 KoiwaiTomomi 2 HiratsukaMiyuki 2 FukumuraMakiko 2 KonoTakako 1 UenoHideki 2 YamamotoJunji 2 TsudaHitoshi 1 Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan Department of Surgery, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan Correspondence to: Dr Takahiro Einama, Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan, E-mail: titiuehahaue@hotmail.com 03 2019 14 01 2019 17 3 2818 2824 24062018 13112018 Copyright: © Yamagishi et al. 2019 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The present study reports a case of metachronous bilateral breast cancer associated with neurofibromatosis type 1 (NF1). A 67-year-old female, who had undergone a radical mastectomy of the left breast 34 years ago due to breast cancer, presented with a tumor of the right breast. The clinical stage of the original breast cancer was T2N0M0 stage IIA and adjuvant chemotherapy had not been not administered. With regard to the right-sided breast tumor, on physical examination, multiple neurofibromas and café-au-lait spots were found to be scattered over the skin. A 2-cm tumor was palpable. The preoperative histopathological diagnosis of the right-sided breast tumor was invasive ductal carcinoma, T2N0M0 stage IIA, with negative results for hormone receptors and human epidermal growth factor receptor 2. The patient underwent a modified radical mastectomy and axillary node dissection, and received adjuvant chemotherapy. The bilateral tumors were similar in histology and immunophenotype, each being histological grade 3, triple-negative and with a basal-like subtype. Based on a literature review of 90 breast cancers in 84 patients with NF1 (84 patients, 90 breasts), younger age onset, advanced clinical stage and hormone receptor negativity were characteristic features. Bilateral cancer occurred in 8.3% of patients and was characterized by ER negativity, earlier stage and younger age compared with patients with unilateral cancer.

 Introduction

Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is an autosomal dominant disorder that manifests as a number of symptoms, including pigmentary changes (café-au-lait spots, skin fold freckling and Lisch nodules) and neurofibromas (1). NF1 is known to occur by heterozygous germ-line mutation of the NF1 gene, which is located on the pericentromeric region of the long arm of chromosome 17 and encodes the 327-kd protein known as neurofibromin (2,3). The function of neurofibromin remains unknown. Patients with NF1 have an increased risk for the development of malignancies, particularly malignant peripheral nerve sheath tumors, optic and other glioma types, including cerebellar astrocytomas, ependymomas third-ventricle astrocytomas, cerebral astrocytomas, brain stem gliomas and spinal cord tumors, and leukemia and breast cancer (4). The characteristics of patients with breast cancer with NF1 have been reported to include negative estrogen receptor (ER), negative progesterone receptor (PgR), amplified human epidermal growth factor receptor 2 (HER2), higher tumor grade, and low 5-year survival rate compared with the control group (5). As the NF1 gene and the breast cancer susceptibility gene 1 (BRCA1) DNA repair-associated gene are located on the long arm of chromosome 17, an association between the two genes has been reported (6).

The present study reports the case of a female patient who exhibited typical NF1 and was diagnosed with metachronous bilateral breast cancer. In addition, a literature review is presented of reported Japanese cases.

 Case report

A 67-year-old female was referred to the National Defense Medical College Hospital (Saitama, Japan) due to a palpable lump in the right breast in December 2016. The past medical history of the patient included NF1 at the age of 25 years and a Halsted radical mastectomy for left-sided breast cancer (T2N0M0 stage IIA) at the age of 33 years. Following this original surgery, the patient did not receive adjuvant chemotherapy.

During the present physical examination, a 2-cm tumor was palpated in the upper-outer quadrant of the right breast. The patient presented with classical NF1, indicated by neurofibromas over the trunk (Fig. 1). A high-density microlobulated mass with microcalcifications was observed in the right breast on a mammogram (Fig. 2). The mass was 1.8×1.7 cm in size on ultrasound. Core needle biopsy specimens from the mass revealed invasive ductal carcinoma. Under the clinical diagnosis of T2N0M0 right-sided breast cancer, the patient underwent a modified radical mastectomy and sentinel node biopsy. As the sentinel node was intraoperatively diagnosed as positive for cancer, an axillary dissection was also performed.

The histopathological diagnosis of the surgically-resected specimens was invasive ductal carcinoma of no special type, nuclear grade 3 (Fig. 3A and B). The right-sided breast tumor was negative for ER, PgR and HER2. The Ki-67 labeling index was 26.5% (Fig. 3C-F). On histological review of the surgical specimens from the left-sided breast cancer obtained 34 years ago, the invasion range of the tumor was 5.0 cm, and the tumor was diagnosed as an invasive, ductal, solid-tubular carcinoma, nuclear grade 3 (Fig. 4A and B). The pathological features of these bilateral types of breast cancer were similar. The left-sided breast cancer was also negative for ER, PgR and HER2, with a Ki-67 labeling index of 74.0% (Fig. 4C-F). The tumors were positive for the basal-like markers epidermal growth factor receptor (EGFR) and cytokeratin 5/6, and partially positive for vimentin. The patient is currently undergoing adjuvant therapy with epirubicin and cyclophosphamide, and treatment with docetaxel, with no evidence of recurrence in the 20 months following the most recent surgical treatment, according to the patient's 3 month follow-ups.

 Materials and methods <sec> <title>Histological examination and immunohistochemistry

Histological examination was performed on the surgically-resected specimens fixed with 10% formalin for 24 h at room temperature. Paraffin-embedded sections (thickness, 4-µm) was performed using hematoxylin-eosin (H&E) staining. For H&E staining, sections were stained with 0.12 g/v% hematoxylin solution produced by Hematoxylin (C.I. 75290) cryst. (cat. no. 104302; Merck KGaA, Darmstadt, Germany) three times for 3 min/stain at room temperature, and with eosin Y (cat. no. 058-00062; Wako Pure Chemical Industries, Ltd., Osaka, Japan) two times for 1.5 min/stain at room temperature. The sections were treated with 5% hydrogen peroxide for 5 min, followed by incubation with 0.4% block ace (cat. no. UK-B80; DS pharma, Japan) for 10 min at room temperature. The following commercially available primary antibodies were used: ER (cat. no. IR084; dilution, 1:100); PgR (cat. no. IR068; dilution, 1:100); HER2 (cat. no. A0485; dilution, 1:100); Ki-67 (cat. no. M7240); Cytokeratin 5/6 (CK5/6; cat. no. M7237; dilution, 1:50) and Vimentin (cat. no. M0725; dilution, 1:500; all Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) at 4°C overnight, and subsequently incubated with Histofine Simplestain Max PO (cat. no. 424151; Nichirei Biosciences, Inc. Tokyo, Japan) as the secondary antibody for 1 h at room temperature. Immunohistochemical staining for EGFR was performed using the EGFR pharmDx™ kit (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA). Sections were deparaffinized in three sequential xylene baths for 5 min at room temperature, 100% ethanol for 3 min and 95% ethanol for 3 min, followed by a 5-min single wash in wash-buffer solution (Dako; Agilent Technologies, Inc.). Subsequently, at room temperature, the section was rinsed in wash-buffer for 5 min, incubated in proteinase K solution (Dako; Agilent Technologies, Inc.) for 5 min, rinsed again in the wash-buffer for 5 min, incubated in peroxidase blocking agent for 5 min at room temperature, rinsed, incubated with the primary EGFR antibody (clone 2-18C9, mouse monoclonal, prediluted) for 30 min at room temperature, rinsed, incubated with visualization reagent for 30 min, rinsed twice with the buffer, incubated with 3,3′-Diaminobenzidine for 5 min at room temperature and finally rinsed again with the buffer. Slides were counterstained with 0.12 g/v% hematoxylin solution produced by Hematoxylin cryst. (C.I. 75290; cat. no. 104302; Merck KGaA, Darmstadt, Germany) three times for 3 min/stain at room temperature, and rinsed gently in reagent quality water. Slides were observed under a fluorescent microscope (magnification, ×40, ×200, and ×400).

 Histological study

ER and PgR were assessed by immunohistochemistry and defined as positive when ≥1% of constituent carcinoma cells were immunoreactive (7). Judgment of HER2 was made according to the American Society of Clinical Oncology/College of American Pathologists guideline 2013 (8). Ki-67 was evaluated according to the recommendation of Breast Cancer Working Group (9). Histological diagnosis and pathological stage were determined by the clinical and pathological recording of breast cancer by Union for International Cancer Control (UICC) (10).

 Statistical analysis

A total of 90 previously reported cases of breast cancer in 84 Japanese patients with NF1 were assessed. Furthermore, the 90 cases of breast cancer associated with NF1 were compared with the 86,478 cases of the Breast Cancer Registry of the Japanese Breast Cancer Society in 2015 as a reference population (11). The compared parameters were laterality, age, UICC pStage, histological type, ER, PgR, HER2. A total of 82,842 patients without distant metastasis, histological type, ER, PgR, and HER2 were examined. The χ2 test or Fisher's exact test was used to determine the association between patients with NF1 and the general population, for bilateral and unilateral breast cancer, and other parameters, in patients with NF1. Differences were considered statistically significant when P<0.05. All statistical analyses were performed using JMP® Pro 12 (SAS Institute Inc., Cary, NC, USA). Results are discussed in Tables I and II and the Discussion section.

 Discussion

NF1 is an autosomal dominant genetic disorder caused by germline mutation of the NF1 gene, with an estimated birth incidence of 1 in 2,000–5,000 individuals (12). In total, 40,000 people are estimated to be affected in Japan (1). The diagnosis of NF1 is made based on the presence of >6 café-au-lait spots and multiple neurofibromas. In patients with NF1, half do not present with a family history, and therefore, the disease is considered to be caused by a de novo germline NF1 mutation (13).

Patients with NF1 have an increased risk of developing malignant peripheral nerve sheath tumors, optic and other gliomas, including cerebellar astrocytomas, ependymomas third-ventricle astrocytomas, cerebral astrocytomas, brain stem gliomas, and spinal cord tumors, and leukemia (4). Epidemiological studies have demonstrated that patients with NF1 are 4-times more likely to develop malignant tumors compared with the general population (14,15). Furthermore, the risk of breast cancer in younger patients with NF1 (<50 years old) has been reported to be 2.68- to 4.9-times higher compared with that in the general population (16–18). Screening mammography is recommended for women ≥40 years old who are affected by NF1 (16). The number of ductal carcinoma in situ (DCIS) cases has risen with the recent increase in breast cancer screening. Uusitalo et al (5) reported that 32 out of 1,404 patients with NF1 were diagnosed with breast cancer. In this study, the characteristics of patients with breast cancer with NF1 included negative ER, negative PgR and amplified HER2 results, higher tumor grade and a low 5-year survival rate (68.1% in patients with NF1 vs. 82.0% in the control group).

A total of 90 previously reported cases of breast cancer in 84 Japanese patients with NF1 were assessed (Table I) (11). In one case of bilateral breast cancer, the details of the initial breast cancer were unknown. The mean age of these patients with breast cancer was 52.6 years (range, 25–88 years). Only in one case was the patient male. The rate of bilateral breast cancer was 8.3% (7/84). When the 90 cases of breast cancer associated with NF1 were compared with the 86,478 cases of breast cancer resected in Japan in 2015 as a reference population, the NF1-associated breast cancers were characterized by a younger age (P<0.0001), a more advanced clinical stage (P<0.0001), and ER and PgR negativity (P<0.0001). Among the patients with breast cancer associated with NF1, the percentage of patients <35 years was 11.9%, which was higher compared with that in the reference group (1.8%). Nakamura et al (19) similarly reported that the rate of patients with breast cancer and NF1 who were ≤35 years was 18.5%. Among the 90 cases of breast cancer, only 16.7% (15/90) were diagnosed as early-stage breast cancer (UICC; stage 0 or I). Therefore, the majority of cases were diagnosed at stage II or at a more advanced stage. Murayama et al (20) considered that breast tumors were overlooked until they increased in size due to the symptoms of systemic neurofibromatosis. In the present case, only following an extensive amount of time (2 years) did the patient realize that the breast tumor may be different from a skin tumor. In addition, the present case verified that another characteristic of NF1-associated breast cancer is ER (22/36, 61.1%) and PgR (23/34, 67.6%) negativity. With regard to HER2, Uusitalo et al (5) reported that HER2 was positive in 30.8% of NF1-associated breast cancers. However, in the present literature review, the HER2-positive rate was only 16.7% (1/6).

Following the division of the 84 patients into two groups representing unilateral and bilateral cancer, it was observed that the clinicopathological characteristics slightly differed. The rate of ER-negative tumors was higher among the bilateral NF1 cases compared with that among the unilateral NF1 cases (100% vs. 53%; P=0.063), although there was no statistical difference. Likewise, bilateral cases had a higher percentage of stage 0 or I breast cancer, DCIS and patients <35 years old compared with unilateral cases, although these results were not statistically significant (Table II). There was no significant difference in PgR or HER2 status between the unilateral and bilateral groups.

The NF1 gene is located on the pericentromeric region of the long arm of chromosome 17. This gene encodes neurofibromin, which is composed of 59 exons, spanning 350 kD of genomic DNA; it inhibits Ras activity by facilitating the conversion of active Ras-GTP to inactive Ras-GDP (21).

The NF1 and BRCA1 genes are located on the long arm of chromosome 17, and are topologically relatively close to each other with a genetic distance of 20 cM. Ceccaroni et al (6) reported that two linked mutations at NF1 and BRCA1 caused concurrent NF1, and hereditary breast and ovarian cancer (HBOC) in the same family. In addition, previous reports have examined single germline mutations in NF1 and BRCA1 genes in the same individual (22,23). In these reports, examination of a BRCA1 gene mutation as an early screening method for patients with NF1 was indicated to aid the early detection of breast cancer, thus reducing morbidity and mortality rates.

In the National Comprehensive Cancer Network guidelines for genetic/familial high-risk assessment of breast and ovarian cancer, detailed genetic risk assessment is recommended for patients ≤50 years old, for patients ≤60 years old with triple-negative breast cancer and for patients with a history of two primary types of breast cancer (24). Based on the aforementioned criteria, the present patient had a high genetic risk for HBOC, and genetic testing for BRCA1/2 may have been beneficial for early detection of the second breast cancer.

In summary, the present study reports the case of an NF1 patient with metachronous bilateral breast cancer. The two breast cancers were diagnosed as triple-negative and basal-like subtype by immunohistochemistry. Based on a literature review of 84 patients, a younger age onset, an advanced clinical stage and hormone receptor negativity were indicated to be characteristic features of breast cancer in patients with NF1.

 Acknowledgements

Not applicable.

 Funding

The present study was supported in part by a grant-in-aid for defense medicine from the Ministry of Defense and a grant-in-aid from the Foundation for Promotion of Defense Medicine.

 Availability of data and materials

The findings used and/or analyzed during this published article are available from the corresponding author on reasonable request.

 Authors' contributions

YY, TE and HT collaborated in the conception and design of the study. YY, TY, ToK, MH, MF, and TaK acquired the data. YY, TE, TY, ToK, MH, MF, TaK, HU, JY and HT performed data analysis and interpretation. All authors were involved in writing the manuscript. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Written informed consent was provided by the patient for publication of this study.

 Competing interests

The authors declare that they have no competing interests.

 References YoshidaYKuramochiAOhtaAFurumuraMImafukuSMatsuoMChikudaHFunasakiHSaitoKSayaHDiagnostic criteria and treatment guidelines for nerve fibrosis type 1 (Recklinghausen's disease)Jpn J Dermatol118165716662008(In Japanese) WallaceMRMarchukDAAndersenLBLetcherROdehHMSaulinoAMFountainAMBreretonANicholsonJMitchellALType 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patientsScience249181186199010.1126/science.21347342134734 GottfriedONViskochilDHCouldwellWTNeurofibromatosis Type 1 and tumorigenesis: Molecular mechanisms and therapeutic implicationsNeurosurg Focus28E8201010.3171/2009.11.FOCUS0922120043723 KorfBRMalignancy in neurofibromatosis type 1Oncologist5477485200010.1634/theoncologist.5-6-47711110599 UusitaloEKallionpääRAKurkiSRantanenMPitkäniemiJKronqvistPHärkönenPHuovinenRCarpenOPöyhönenMBreast cancer in neurofibromatosis type 1: Overrepresentation of unfavourable prognostic factorsBr J Cancer116211217201710.1038/bjc.2016.40327931045 CeccaroniMGenuardiMLeggeFLucci-CordiscoECarraraSD'AmicoFGreggiSScambiaGBRCA1-related malignancies in a family presenting with von recklinghausen's diseaseGynecol Oncol86375378200210.1006/gyno.2002.675712217765 HammondMEHayesDFDowsettMAllredDCHagertyKLBadveSFitzgibbonsPLFrancisGGoldsteinNSHayesMAmerican society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerArch Pathol Lab Med134907922201020524868 WolffACHammondMEHicksDGDowsettMMcShaneLMAllisonKHAllredDCBartlettJMBilousMFitzgibbonsPRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateJ Clin Oncol3139974013201310.1200/JCO.2013.50.998424101045 DowsettMNielsenTOA'HernRBartlettJCoombesRCCuzickJEllisMHenryNLHughJCLivelyTAssessment of Ki67 in breast cancer: Recommendations from the international Ki67 in breast cancer working groupJ Natl Cancer Inst10316561664201110.1093/jnci/djr39321960707 BrierleyJDGospodarowiczMKWittekindCTNM Classification of Malignant Tumours8thWiley-BlackwellChichester2017 SalemisNSNakosGSambaziotisDGourgiotisSBreast cancer associated with type 1 neurofibromatosisBreast Cancer17306309201010.1007/s12282-009-0119-719466510 RasmussenSAFriedmanJMNF1 gene and neurofibromatosis 1Am J Epidemiol1513340200010.1093/oxfordjournals.aje.a01011810625171 TakanoTKawashimaTYamanouchiYKitayamaKUenoKHamaguchiHGenetics of neurofibromatosis 1 in Japan: Mutation rate and paternal age effectHum Genetics89281286199210.1007/BF00220540 SorensenSAMulvihillJJNielsenALong-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasmsN Engl J Med31410101015198610.1056/NEJM1986041731416033083258 ZollerMERembeckBOdenASamuelssonMAngervallLMalignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish populationCancer7921252131199710.1002/(SICI)1097-0142(19970601)79:11<2125::AID-CNCR9>3.0.CO;2-N9179058 SharifSMoranAHusonSMIddendenRShentonAHowardEEvansDGWomen with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screeningJ Med Genet44481484200710.1136/jmg.2007.04934617369502 WalkerLThompsonDEastonDPonderBPonderMFraylingIBaralleDA prospective study of neurofibromatosis type 1 cancer incidence in the UKBr J Cancer95233238200610.1038/sj.bjc.660322716786042 MadanikiaSABergnerAYeXBlakeleyJOIncreased risk of breast cancer in women with NF1Am J Med Genet A158a30563060201210.1002/ajmg.a.3555023165953 NakamuraMTangokuAKusanagiHOkaMSuzukiTBreast cancer associated with Recklinghausen's disease: Report of a caseNihon Geka Hokan6739199810401230 MurayamaYYamamotoYShimojimaNTakaharaTKikuchiKIidaSKondoYT1 Breast cancer associated with von recklinghausen's neurofibromatosisBreast Cancer6227230199910.1007/BF02967173 XuGFLinBTanakaKDunnDWoodDGestelandRWhiteRWeissRTamanoiFThe catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiaeCell63835841199010.1016/0092-8674(90)90149-92121369 JeonYWKimRMLimSTChoiHJSuhYJEarly-onset breast cancer in a family with neurofibromatosis type 1 associated with a germline mutation in BRCA1J Breast Cancer1897100201510.4048/jbc.2015.18.1.9725834617 CamposBBalmanaJGardenyesJValenzuelaIAbadOFàbregasPVolpiniVDíezOGermline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancerBreast Cancer Res Treat139597602201310.1007/s10549-013-2538-623624750 DalyMBPilarskiRBerryMBuysSSFarmerMFriedmanSGarberJEKauffNDKhanSKleinCNCCN Guidelines insights: Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017J Natl Compr Canc Netw15920201710.6004/jnccn.2017.000328040716

Multiple neurofibromas on the skin. The left-sided breast cancer was resected by radical mastectomy 35 years prior.

Mammogram of a 67-year old female patient, indicating a high-density microlobulated mass with microcalcifications and neurofibromas (Arrows).

Histopathological features of the right-sided breast cancer. (A and B) The histological diagnosis was invasive ductal carcinoma, scirrhous carcinoma, grade 3, as observed by hematoxylin and eosin staining at magnification (A) ×40 and (B) ×400. Immunohistochemical features of (C) ER, (D) PgR and (E) HER2. Stains for ER, PgR and HER2 were all negative. (F) The Ki-67 labeling index was 26.5% [(C-F) ×200 magnification; immunoperoxidase staining]. ER, estrogen receptor; PgR, progesterone receptor; HER2 human epidermal growth factor receptor 2.

Histopathological features of the previous left-sided breast cancer. The histological diagnosis was invasive ductal carcinoma, solid-tubular carcinoma, grade 3, as observed by hematoxylin and eosin staining at magnification (A) ×40 and (B) ×400. Immunohistochemical features of (C) ER, (D) PgR and (E) HER2. ER, PgR and HER2 staining results were all negative. (F) The Ki-67 labeling index was 74.0% [(C-F) magnification, ×200; immunoperoxidase staining]. ER, estrogen receptor; PgR, progesterone receptor; HER2 human epidermal growth factor receptor 2.

Comparison of clinicopathological features between patients with breast cancer with neurofibromatosis type 1 (11) and patients with breast cancer surgically resected in Japan in 2015.

Parameter NF1 patients (n=84; n=90 affected breasts) General population (n=86,478; n=86,478 breasts) P-value
Laterality, n (%) 0.8532
  Unilateral 77 (91.7) 78,173 (90.4)
  Bilateral 7 (8.3) 8,305 (9.6)
Age, years <0.0001
  Median, range 53, 25–88 60, unknown
  <35, n (%) 10 (11.9) 1,579 (1.8)
  ≥35, n (%) 72 (85.7) 84,775 (98.0)
  Unknown, n (%) 2 (2.4) 124 (0.2)
UICC pStage, n (%) (10) <0.0001
  0, I 15 (16.7) 46,662 (53.9)
  II, III, IV 61 (67.8) 37,334 (43.2)
  Unknown 14 (15.6) 2,482 (2.9)
Histological type, n (%) <0.0001
  DCIS 4 (4.4) 10,908 (13.2)a
  IDC 58 (64.4) 59,941 (72.3)a
  Special type 18 (20.0) 10,212 (12.3)a
  Unknown 10 (11.1) 1,781 (2.2)a
ER, n (%) <0.0001
  Positive 14 (15.6) 60,768 (73.4)a
  Negative 22 (24.4) 12,021 (14.5)a
  Unknown 54 (60.0) 10,053 (12.1)a
PgR, n (%)
  Positive 11 (12.2) 52,997 (64.0)a <0.0001
  Negative 23 (25.6) 19,330 (23.3)a
  Unknown 56 (62.2) 10,515 (12.7)a
HER2, n (%) >0.999
  Positive 1 (1.1) 9,817 (11.9)a
  Negative 5 (5.6) 54,702 (66.0)a
  Unknown 84 (93.3) 18,323 (22.1)a

Denominator of 82,842 breast cancer cases. ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma of no special type; UICC, Union for International Cancer Control.

Comparison of clinicopathological factors between bilateral breast cancer and unilateral breast cancer in patients with neurofibromatosis type 1.

Parameter Bilateral breast cancer (n=7; n=13 affected breasts) Unilateral breast cancer (n=77; n=77 affected breasts) P-value
Age at first breast cancer, years 0.1542
  Median, range 45, unknown 53, unknown
  <35, n (%) 2 (28.6) 8 (10.4)
  ≥35, n (%) 4 (57.1) 68 (88.3)
  Unknown, n (%) 1 (14.3) 1 (1.3)
UICC pStage, n (%) (10) 0.1178
  0, I 5 (38.5) 10 (13.0)
  II, III, IV 8 (61.5) 53 (68.8)
  Unknown 0 (0) 14 (18.2)
Histological type, n (%) 0.1030
  DCIS 2 (15.4) 2 (2.6)
  IDC 9 (69.2) 49 (63.6)
  Special type 1 (7.7) 17 (22.1)
  Unknown 1 (7.7) 9 (11.7)
ER, n (%) 0.0625
  Positive 0 (0) 14 (18.2)
  Negative 6 (46.2) 16 (20.8)
  Unknown 7 (53.8) 47 (61.0)
PgR, n (%) 0.6379
  Positive 1 (7.7) 10 (13.0)
  Negative 5 (38.5) 18 (23.4)
  Unknown 7 (53.8) 49 (63.6)
HER2, n (%) >0.9999
  Positive 0 (0) 1 (1.3)
  Negative 2 (15.4) 3 (3.9)
  Unknown 11 (84.6) 73 (94.8)

ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma of no special type; UICC, Union for International Cancer Control.